ISSN: 2306-6091

International Journal of Pharmaceuticals and Health care Research (IJPHR)

IJPHR |Vol.13 | Issue 2 | Apr - Jun -2025

www.ijphr.com

DOI : https://doi.org/10.61096/ijphr.v13.(SPL 1).2025.228-235

Review

A Critical Review Of The Adverse Effects Of Commonly Prescribed Painkillers

[1*]Lokesh Rawat, [2]Narendra Singh

Research Scholar, Maya College of Pharmacy, Dehradun
Assistant Professor, School of Pharmacy, Maya Devi University, Dehradun

*Author for Correspondence: Lokesh Rawat
Email: lokeshrawat752@gmail.com

Published on: 04 Jun 2025

Published by:
DrSriram Publications

Abstract

Painkillers play a crucial role in managing acute and chronic pain, significantly improving patients' quality of life. However, commonly used analgesics such as NSAIDs, opioids, and acetaminophen are associated with serious side effects that can outweigh their therapeutic benefits. This review critically examines the safety profiles, mechanisms of toxicity, and clinical implications of these drugs. NSAIDs, though effective for pain and inflammation, inhibit COX-1 enzymes and are linked to gastrointestinal issues like ulcers and bleeding, along with increased risks of cardiovascular events and kidney damage. Opioids, vital for severe pain relief, carry significant risks including respiratory depression, constipation, tolerance, dependence, and endocrine disruption issues that have contributed to the ongoing opioid crisis. Acetaminophen, often viewed as a safer option, poses a risk of acute liver failure when taken in high doses due to the buildup of toxic metabolites. The review also discusses adjuvant analgesics used for neuropathic pain, which can further complicate treatment through side effects and polypharmacy challenges. Given these risks, it is essential to perform individualized risk-benefit assessments, prescribe the lowest effective doses, and ensure patient education and regular monitoring. Future strategies should focus on developing safer analgesics and updating clinical guidelines to enhance pain management and reduce complications.

Keywords: Painkillers, Adverse effects, NSAIDs, Opioids, Hepatotoxicity

1. INTRODUCTION

An essential defence mechanism, pain is a basic and universal human experience. However, an individual's quality of life and functional ability are greatly impacted when pain becomes chronic or

unmanageable[1]. Therefore, in almost every speciality, effective pain management is a fundamental aspect of medical practice. Among the pharmacological options for pain management, analgesics, also known as painkillers, are among the most commonly prescribed drugs in the world. These include paracetamol (paracetamol), opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and some adjuvant medications like antidepressants and anticonvulsants, especially for neuropathic pain[2]. Even though these drugs are frequently necessary to lessen suffering and enhance patient outcomes, using them carries a significant risk. A growing amount of data has shown that using them can have a variety of negative effects, ranging from minor discomfort to serious and potentially fatal complications[3]. A persistent conflict between attaining effective analgesia and preventing harm characterises the clinical use of painkillers. For instance, because of their analgesic, antipyretic, and anti-inflammatory qualities, NSAIDs are frequently used to treat a range of pain conditions[4].

However, long-term or improper NSAID use is associated with cardiovascular problems, renal dysfunction, and gastrointestinal bleeding, particularly in susceptible groups like the elderly and people with underlying renal or cardiovascular diseases. Similar to this, opioids, the most powerful class of analgesics, are crucial for treating acute pain and pain associated with cancer. However, because of their high potential for tolerance, dependence, abuse, and overdose, their use has led to a public health emergency. Another common analgesic, paracetamol, is one of the main causes of hepatotoxicity globally[5].

Although it is usually well tolerated at therapeutic dosages, even small overdoses can result in acute liver failure. The difficulty of safely and effectively prescribing painkillers is demonstrated by these examples. Pain is a complex phenomenon with elements of perception, emotion, thought, and behaviour. As a result, pharmacological pain management needs to be just as complex and unique. Although they alleviate symptoms, painkillers have physiological effects that go beyond pain pathways. For example, NSAIDs reduce inflammation and prostaglandin synthesis by blocking the cyclooxygenase enzymes COX-1 and COX-2. However, this mechanism also impacts renal perfusion and the protective lining of the gastrointestinal tract.

In addition to effectively blocking the transmission of pain by binding to opioid receptors in the central nervous system, opioids also depress respiratory centres, impair bowel motility, and change mood and cognitive abilities[6]. Although its exact mechanism of action is unknown, even acetaminophen involves central prostaglandin inhibition and can be harmful to the liver when metabolised to reactive intermediates in excess. Factors like patient comorbidities, polypharmacy, and noncompliance with evidence-based prescribing guidelines exacerbate the clinical difficulties related to the use of analgesics[7]. Adverse events are more likely in many settings where patients self-medicate or are not properly monitored. Furthermore, combination therapies which are frequently used to treat chronic or refractory pain are especially dangerous due to the overlapping toxicity profiles of various painkillers. For instance, patients who are prescribed NSAIDs for musculoskeletal pain might also be taking low-dose aspirin for cardioprotection, which increases the risk of kidney and gastrointestinal problems. Likewise, opioids are frequently mixed with other drugs that depress the central nervous system, which raises the risk of sedation and respiratory depression[8].

The general public's belief that over-the-counter (OTC) analgesics are always safe is another issue. This has resulted in the improper and unsupervised use of drugs such as paracetamol and ibuprofen, which has increased the burden of drug-related complications. In low- and middle-income nations, where access to medical professionals is frequently restricted and regulatory oversight may be weak, the issue is made worse. Misinformation and insufficient patient education can result in dangerous behaviours like dose escalation, prolonged use without reassessment, and mixing medications with similar mechanisms of toxicity, even in healthcare systems with strict regulations. It is essential to critically examine the safety profiles of frequently prescribed painkillers in light of these concerns[9]. Even though a lot of research has shown the negative effects of each one separately, more information needs to be compiled to help physicians, chemists, and legislators create safer and more efficient pain management plans. This entails being aware of the clinical risk factors that put patients at risk for negative outcomes in addition to the pharmacological mechanisms of toxicity. Age, underlying organ dysfunction, genetic predispositions, and concurrent use of interacting drugs are a few examples of such factors. Additionally, because of their distinct physiological reactions and risk profiles, special populations such as elderly people, children, and pregnant women need special attention.

Ignoring the negative effects of painkillers can have far-reaching consequences. In addition to the direct health risks to individuals, hospital stays, long-term care, and lost productivity have significant financial costs. Tens of thousands of people die each year as a result of the opioid epidemic alone, which has also put a strain on the legal and public health systems[10]. Hospitalisations brought on by NSAIDs because of renal problems and gastrointestinal bleeding place a heavy strain on healthcare systems. Furthermore, the ethical ramifications of either overtreating or undertreating pain both of which indicate subpar medical care—are becoming increasingly apparent. A diversified strategy is needed to address these issues. Clinicians must possess current information about the advantages and disadvantages of different analgesics and be able to use this information in a way that is patient-centered. Systems for pharmacovigilance should be improved in order to quickly identify and address adverse events linked to drugs. Promoting responsible drug use can be greatly aided by education initiatives aimed at the general public and medical professionals. Furthermore, there is an

immediate need for research into novel classes of analgesics with enhanced safety profiles. There is hope for more individualised and focused approaches to pain management thanks to developments in areas like pharmacogenomics and molecular medicine, which will lessen the need for broad-spectrum analgesics with strong systemic effects[11].

In conclusion, even though painkillers are essential to contemporary medicine, their use needs to be carefully considered in light of the risks involved. To improve patient outcomes and direct future therapeutic developments, a thorough understanding of the side effects linked to commonly prescribed analgesics is crucial. The purpose of this review is to critically assess these risks, provide helpful suggestions for safer prescribing, and investigate new approaches that could lead to a more well-rounded and successful pain management strategy[12].

2. Commonly Prescribed Painkillers and Their Adverse Effects

Pharmacological agents known as analgesics, or painkillers, are used to treat mild to severe pain. In clinical settings, they are essential for treating a variety of ailments, including cancer pain, neuropathic pain, arthritis, post-operative pain, and pain from injuries. Notwithstanding their therapeutic advantages, the extensive and occasionally careless use of these medications has been connected to a number of negative side effects, ranging from minor discomfort to potentially fatal situations. Acetaminophen (paracetamol), opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and some adjuvant analgesics are the most often prescribed painkillers. This section critically examines these medications, highlighting their modes of action and related side effects[13].

2.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

NSAIDs are some of the most commonly used analgesics in the world. They work by preventing the production of prostaglandins, which are involved in inflammation, fever, and pain, by the cyclooxygenase enzymes (COX-1 and COX-2). Ibuprofen, naproxen, diclofenac, indomethacin, and selective COX-2 inhibitors like celecoxib are examples of NSAIDs that are frequently used[14].

Adverse Effects

i. **Gastrointestinal (GI) Toxicity**: Gastrointestinal toxicity is the most common side effect linked to NSAIDs. When COX-1 is inhibited, the gastric mucosa produces fewer protective prostaglandins, which causes bleeding, ulceration, and mucosal erosion. Peptic ulcers brought on by NSAIDs are a major cause of hospitalizations and morbidity, especially in the elderly.

ii. **Renal Impairment**: By lowering renal prostaglandin synthesis, NSAIDs can affect renal function by lowering glomerular filtration rate (GFR) and renal blood flow. Patients who already have heart failure, renal insufficiency, or are on nephrotoxic medications should be especially concerned about this effect[15].

iii. **Cardiovascular Risks**: A higher risk of cardiovascular events like myocardial infarction and stroke has been associated with some NSAIDs, especially COX-2 inhibitors. It is believed that the mechanism involves an imbalance between prostacyclin, which inhibits platelet aggregation and vasodilation, and thromboxane, which promotes platelet aggregation.

iv. **Hematologic and Hepatic Effects**: Long-term NSAID use can lead to hepatitis, elevated liver enzymes, and, in rare instances, liver failure. It can also cause blood dyscrasias like thrombocytopenia and agranulocytosis.

2.2. Opioid Analgesics

Opioids are strong analgesics that mainly affect the central nervous system by modifying pain perception through binding to the mu, delta, and kappa opioid receptors. Morphine, codeine, oxycodone, hydrocodone, fentanyl, tramadol, and methadone are examples of common opioids. They are frequently prescribed to treat cancer-related pain, chronic pain, and moderate to severe acute pain[16].

Adverse Effects

i. **Respiratory Depression**: One of the most dangerous side effects of opioids is respiratory depression, which can be lethal, especially in people who have never used opioids before or when combined with other drugs that depress the central nervous system, such as alcohol or benzodiazepines.

ii. **Constipation and Gastrointestinal Dysfunction**: Constipation, bloating, nausea, and vomiting are caused by opioids' suppression of gastrointestinal motility. Constipation brought on by opioids is among the most frequent and enduring adverse effects.

iii. **Tolerance, Dependence, and Addiction**: As a result of tolerance brought on by repeated opioid use, higher dosages may be needed to produce the same analgesic effect. Consequently, this raises the

possibility of addiction and physical dependence. The worldwide opioid crisis has been greatly exacerbated by the abuse of prescription opioids[17].

iv. **Neurocognitive Impairments**: Chronic opioid use is linked to psychomotor impairment, drowsiness, sedation, and cognitive dysfunction, all of which can impair day-to-day functioning and raise the risk of accidents.

v. **Endocrine Effects**: The hypothalamic-pituitary-gonadal axis can be suppressed by long-term opioid use, resulting in hormonal imbalances like low testosterone, irregular menstruation, and decreased libido.

vi. **Immunosuppression**: According to certain research, long-term opioid treatment may weaken the immune system, raising the possibility of infections.

2.3. Acetaminophen (Paracetamol)

Acetaminophen is frequently used to treat mild to moderate pain and lower fevers. Its precise mode of action is unclear, but it is thought to work centrally by preventing the synthesis of prostaglandins. For patients with gastrointestinal or cardiovascular risks, it is thought to be safer than NSAIDs; however, when used improperly, it poses major risks[18].

Adverse Effects

i. **Hepatotoxicity:** Hepatotoxicity, which mostly happens in overdose cases, is the most dangerous side effect of acetaminophen. Excess acetaminophen is broken down in the liver into a toxic metabolite called NAPQI, which can deplete the liver's glutathione reserves and cause acute liver failure and damage to liver cells.

ii. **Nephrotoxicity :** Chronic high-dose acetaminophen use has been linked to renal toxicity, including acute tubular necrosis and interstitial nephritis, though this is less common.

iii. **Reactions to Hypersensitivity:** Although they are comparatively uncommon, allergic reactions can range from minor rashes to severe anaphylaxis in certain people[19].

iv. **Interactions with Drugs:** Acetaminophen may increase the risk of bleeding by intensifying the effects of anticoagulants such as warfarin. When taken with alcohol or other hepatotoxic medications, caution is also advised.

2.4. Adjuvant Analgesics

Drugs known as adjuvant analgesics were not initially created to relieve pain, but they have been shown to be useful in treating some forms of pain, especially neuropathic pain. These consist of corticosteroids, antidepressants (like amitriptyline and duloxetine), and anticonvulsants (like gabapentin and pregabalin)[20].

Adverse Effects

i. **Antidepressants:** Sedation, dry mouth, constipation, weight gain, orthostatic hypotension, and cardiotoxicity are all side effects of tricyclic antidepressants (TCAs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Additionally, they may raise the risk of suicidal thoughts, particularly in young adults.

ii. **Anticonvulsants:** Although gabapentin and pregabalin are frequently prescribed for neuropathic pain, they can also result in peripheral edema, cognitive impairment, dizziness, and somnolence. Seizures or withdrawal symptoms may result from abrupt cessation[21].

iii. **Corticosteroid:** Despite being useful in lowering pain associated with inflammation, corticosteroids have a wide range of adverse effects, such as peptic ulcers, mood swings, immunosuppression, hyperglycemia, and osteoporosis.

2.5. Combination Therapies and Polypharmacy

In order to target multiple pain mechanisms or achieve synergistic effects, pain management frequently calls for the use of multiple agents. Combination therapy raises the risk of cumulative toxicity and drug interactions even though it can improve results[22].

Examples and Risks

- Benzodiazepines and opioids can intensify central nervous system depression and cause deadly respiratory events.
- When taken together, NSAIDs and corticosteroids dramatically raise the risk of gastrointestinal bleeding.
- Combination formulations frequently contain acetaminophen, which may unintentionally result in cumulative overdoses.

2.6. Special Populations at Higher Risk

i. **Elderly:** Because of comorbidities, polypharmacy, and age-related changes in drug metabolism and excretion, older adults are more vulnerable to the negative effects of painkillers. The increased risks of gastrointestinal and renal complications make the use of NSAIDs in the elderly particularly concerning[23].

ii. **Children:** Since children's pharmacokinetics differ, pediatric pain management needs to be carefully customized. In this population, opioid dosage errors can be especially harmful.

iii. **Pregnant and Lactating Women:** It is important to exercise caution when using analgesics during pregnancy. Opioids may result in neonatal abstinence syndrome, while NSAIDs during the third trimester may cause the ductus arteriosus to close too soon. Despite being widely regarded as safe, acetaminophen should still be used sparingly[24].

2.7. Economic and Public Health Implications

Hospital stays, prolonged treatments, and lawsuits are some of the ways that the negative effects of painkillers raise healthcare expenses. The opioid crisis alone has cost society billions of dollars in lost productivity, medical expenses, and law enforcement expenses. Furthermore, the abuse of prescription and over-the-counter analgesics has raised the number of deaths, admissions to addiction treatment centers, and ER visits. This emphasizes the necessity of more stringent laws, improved instruction, and stronger monitoring programs[25-27].

3. DISCUSSIONS

In contemporary medicine, the therapeutic use of analgesics is both essential and intricate. Although analgesics like NSAIDs, opioids, and paracetamol have transformed pain management by effectively reducing symptoms in a variety of clinical conditions, there are serious risks associated with their use. A more comprehensive understanding of pharmacological balance between efficacy and safety as well as changing clinical practice patterns and public health implications must be used to frame the conversation about these medications' side effects[28]. For example, nonsteroidal anti-inflammatory drugs (NSAIDs) remain the first choice for treating inflammatory diseases, arthritis, and musculoskeletal pain. Their cardiovascular, renal, and gastrointestinal adverse effects, however, continue to be a serious worry, especially for long-term users and susceptible groups like the elderly. Evidence suggests that these alternatives may raise cardiovascular risk, even though COX-2 selective inhibitors were introduced to reduce GI toxicity[29]. Therefore, thorough patient evaluation and risk-benefit analysis are essential components of clinical decision-making. To lessen NSAID-related side effects, protective co-therapies like proton pump inhibitors and routine renal function testing are frequently required.

Opioids have a much smaller therapeutic window and a high potential for abuse, despite being extremely helpful in treating severe acute pain and pain associated with cancer. The effects of overprescribing and insufficient monitoring have been made evident by the global opioid crisis. The need for stringent regulatory oversight, prescription control initiatives, and the application of opioid stewardship techniques is underscored by respiratory depression, addiction, and tolerance. Reevaluating pain management procedures and creating non-opioid substitutes are also urgently needed, particularly for chronic non-cancer pain. Many people believe that paracetamol is a safe analgesic, especially for those who shouldn't take opioids or NSAIDs. However, increased public awareness and labelling procedures are necessary due to the risk of hepatotoxicity, particularly from accidental overdose or its presence in multiple combination drugs. Healthcare providers should stress the significance of taking no more than the recommended amount of medication each day and steer clear of polypharmacy, which involves using several medications that contain paracetamol[30].

Although adjuvant analgesics like antidepressants and anticonvulsants have increased the number of options for treating neuropathic pain, they also come with a number of side effects, such as sedation, weight gain, and cardiovascular risks. These medications highlight the need for tailored treatment depending on the patient's comorbidities, type of pain, and possible drug interactions. All together, the negative side effects linked to frequently prescribed painkillers highlight the larger difficulty of providing safe and efficient pain management for a variety of patient populations. Negative outcomes are largely caused by self-medication, inappropriate prescribing, and irregular monitoring. Improved patient counselling, clinician education, and the incorporation of non-pharmacological pain management into standard care are all obviously needed. The development of safer analgesics, pharmacovigilance, and personalised medicine must become more important as the healthcare system changes. To address the negative effects of painkillers while still

guaranteeing that patients receive sufficient pain relief, cooperation between clinicians, legislators, researchers, and public health authorities is crucial.

4. CONCLUSION

In clinical practice, painkillers are still essential for treating a variety of acute and chronic pain conditions. The side effects of commonly prescribed analgesics, such as NSAIDs, opioids, and paracetamol, present serious clinical challenges and frequently restrict their safe use despite their effectiveness. Although these drugs offer essential symptom relief, this review has shown that their safety profiles need to be carefully examined to prevent major side effects. NSAIDs are useful for reducing inflammation, but they also have known side effects, such as cardiovascular events, renal impairment, and damage to the gastrointestinal mucosa. The significance of patient-specific risk assessment and monitoring is highlighted by the fact that these negative outcomes are more noticeable in older patients and those with preexisting comorbidities. Some of these risks can be reduced, but not completely eliminated, by using gastroprotective agents and choosing NSAIDs with better safety profiles. Despite their unparalleled analgesic effectiveness, opioids have a number of dangerous side effects, such as constipation, sedation, respiratory depression, and the potential for tolerance, dependence, and abuse. The ongoing opioid crisis serves as a reminder of the risks associated with overprescribing and the urgent need for careful use, thorough patient education, and strict regulatory oversight. To address these issues, multimodal pain management techniques that lessen reliance on opioids are crucial. Although it has a limited therapeutic window, paracetamol is generally considered safe when taken as directed. Overdose hepatotoxicity, which frequently results from inadvertent or deliberate misuse, continues to be a major cause of acute liver failure globally. This necessitates greater knowledge of safe dosage ranges and the dangers of concurrent use with other hepatotoxic medications by both patients and healthcare professionals. Furthermore, because of their unique side effect profiles and possible drug interactions, adjuvant analgesics like antidepressants and anticonvulsants complicate pain management. Although these medications can be helpful for neuropathic pain, they should be used with caution, particularly in patients who are taking other medications. Conclusion: Through customised treatment, cautious patient selection, dose optimisation, and frequent monitoring, effective pain management must strike a balance between analgesic efficacy and the reduction of side effects. Pharmacological developments should keep concentrating on creating analgesics that are less toxic and safer. At the same time, continuous education for patients and healthcare providers is essential to enhancing pain management results and reducing harm. In order to guarantee patient safety and maximise therapeutic success, this critical review highlights the significance of being vigilant and making well-informed decisions when prescribing commonly used painkillers.

5. Challenges and future prospects

There are many difficulties in managing pain with commonly prescribed analgesics, which still affect patient safety and clinical results. Effective pain management while reducing side effects is a major challenge, made more difficult by patient variability in drug response, underlying medical conditions, and polypharmacy, particularly in older or chronically ill patients. The safe therapeutic window for NSAIDs, opioids, and acetaminophen is limited by their inherent risks, which include respiratory depression, dependence, hepatotoxicity, and cardiovascular, renal, and gastrointestinal issues. These side effects frequently result in either overtreatment and misuse, especially with opioids, or undertreatment of pain because prescribers are worried about safety. The opioid crisis highlights the urgent need for better prescribing practices and extensive monitoring systems by illuminating the disastrous effects of lax regulation, overprescribing, and inadequate patient education. In a similar vein, patients with comorbidities face difficulties due to NSAID-related complications, particularly gastrointestinal and cardiovascular risks, necessitating the use of safer analgesic substitutes or efficient risk-reduction techniques. The scarcity of analgesics that combine effectiveness and a wide margin of safety presents another significant obstacle. Individualising therapy without sacrificing safety is challenging because current painkillers frequently target similar pathways with overlapping toxicity profiles. Furthermore, the complex nature of pain, particularly neuropathic and chronic forms, necessitates complicated treatment plans, raising the risk of cumulative negative effects and medication interactions.

In the future, these issues might be resolved by a number of bright prospects. By customising analgesic therapy according to genetic profiles, advances in pharmacogenomics and personalised medicine may increase effectiveness while lowering side effects. The goal of developing new analgesics that target particular pain pathways such as biassed opioid receptor agonists or selective ion channel modulators is to reduce side effects while effectively relieving pain. Furthermore, integrative pain management techniques and non-pharmacological interventions such as physical therapy, cognitive-behavioral therapy, and neuromodulation are becoming more widely acknowledged as essential elements in lowering dependency on medication.

New technologies like wearables and digital health tools may improve patient monitoring by allowing for early adverse event detection and real-time drug effect evaluation. Furthermore, to encourage safer prescribing, enhance adherence, and raise risk awareness, comprehensive educational programs for patients and healthcare professionals are crucial.To sum up, a multimodal strategy that incorporates advancements in drug development, personalised medicine, enhanced clinical procedures, and patient education is needed to address the problems caused by the side effects of frequently prescribed painkillers. These potential developments could lead to safer, more efficient pain management techniques that greatly enhance patient outcomes.

REFERENCES

1. Tobias S, Angelucci J, Wood E, Buxton JA, Ti L. Novel adulterants in unregulated opioids and their associations with adverse events. Canadian Journal of Public Health. 2025 Feb 24:1-8.
2. Trager RJ, Cupler ZA, Srinivasan R, Harper EG, Perez JA. Association between chiropractic spinal manipulation for sciatica and opioid-related adverse events: A retrospective cohort study. PloS one. 2025 Jan 28;20(1):e0317663.
3. Ju J, Li Z, Liu J, Peng X, Gao F. Biased Opioid Receptor Agonists: Balancing Analgesic Efficacy and Side-Effect Profiles. International Journal of Molecular Sciences. 2025 Feb 21;26(5):1862.
4. Trabsky M, Flore J. Prescription Medicine, Adverse Effects and Economies of Death. InEvil Corporations 2025 (pp. 78-90). Routledge.
5. Rau J, Joseph R, Weise L, Bryan J, Wardeh J, Konda A, Duplessis L, Hook MA. Acute Opioid Administration Undermines Recovery after SCI: Adverse Effects Are Not Restricted to Morphine. Journal of Neurotrauma. 2025 Feb 6.
6. Gutiérrez-Cáceres C, Ávila N, Cerpa LC, Martínez MF, Irarrazabal CE, Torres B, Barajas O, Varela NM, Quiñones LA. Association of OPRM1 and OPRD1 Polymorphisms with Pain and Opioid Adverse Reactions in Colorectal Cancer. Pharmaceuticals. 2025 Feb 6;18(2):220.
7. Ramírez Medina CR, Benitez-Aurioles J, Jenkins DA, Jani M. A systematic review of machine learning applications in predicting opioid associated adverse events. npj Digital Medicine. 2025 Jan 16;8(1):30.
8. Davies LE, van den Ham HA, Schellekens AF, Philbert D, Bouvy ML. Patient satisfaction with prescription opioid education in primary care. Patient Education and Counseling. 2025 Feb 1;131:108572.
9. Sonohata M, Kitamura M, Hashimoto A, Morioka Y. Prescription Pattern of Laxatives for Opioid-Induced Constipation in Japanese Patients With Chronic Non-cancer Pain: A Retrospective Cohort Study of a Health Insurance Claims Database. Cureus. 2025 Jan 29;17(1).
10. Schultz DM, Bakke CH, Ruble HL, Larmour CS, Hagedorn JM, Abd-Elsayed A. Intrathecal Drug Delivery for Intractable Pain: Identified Patient Satisfaction Survey Study Comparing Intrathecal Dose With Satisfaction, Pain Relief, and Side Effects. Neuromodulation: Technology at the Neural Interface. 2025 Jan 4.
11. Fitzpatrick D, Leckie T, Heine G, Hodgson L. The use of pain killers (NSAIDs) in athletes: How large is the risk?. Journal of Science and Medicine in Sport. 2024 Nov 28.
12. Zimmerman A, Laitman A. Safe management of adverse effects associated with prescription opioids in the palliative care population: a narrative review. Journal of Clinical Medicine. 2024 May 7;13(10):2746.
13. Gustafsson M, Silva V, Valeiro C, Joaquim J, van Hunsel F, Matos C. Misuse, Abuse and Medication Errors' Adverse Events Associated with Opioids—A Systematic Review. Pharmaceuticals. 2024 Jul 31;17(8):1009.
14. Altawili AA, Altawili MA, Alzarar AH, Abdulrahim NM, Alquraish HH, Alahmari MA, Basyouni MH, Almohaya YA, Alhabshan WM, Alshahrani AM, Alamrad JF. Adverse events of the long-term use of opioids for chronic non-cancer pain: a narrative review. Cureus. 2024 Jan 1;16(1).
15. Le H, Chen R, Harris S, Fang H, Lyn-Cook B, Hong H, Ge W, Rogers P, Tong W, Zou W. RxNorm for drug name normalization: a case study of prescription opioids in the FDA adverse events reporting system. Frontiers in Bioinformatics. 2024 Jan 5;3:1328613.
16. Yuan Y, Xu T, Huang Y, Shi J. Strategies for developing μ opioid receptor agonists with reduced adverse effects. Bioorganic Chemistry. 2024 Jun 3:107507.
17. Oh J, Yeo J. Trends in the prescription of opioids and gabapentinoids in patients with failed back surgery syndrome in Korea: a population-based study. The Korean Journal of Pain. 2024 Jan 1;37(1):73-83.
18. Scott JR, Williams DA, Harte SE, Harris RE, Litinas E, Sisley S, Clauw DJ, Boehnke KF. Relationship between nociplastic pain involvement and medication use, symptom relief, and adverse effects among people using medical cannabis for chronic pain. The Clinical Journal of Pain. 2024 Jan 1;40(1):1-9.
19. Tobias S, Angelucci J, Wood E, Buxton JA, Ti L. Novel adulterants in unregulated opioids and their associations with adverse events. Canadian Journal of Public Health. 2025 Feb 24:1-8.

20. Nguyen CT, McPherson ML, Noble BN, Furuno JP. Prevalence and characteristics of patients prescribed opioids and central nervous system depression agents on discharge to hospice care. Annals of Palliative Medicine. 2024 Mar 31;13(2):24048-248.
21. Patocka J, Wu W, Oleksak P, Jelinkova R, Nepovimova E, Spicanova L, Springerova P, Alomar S, Long M, Kuca K. Fentanyl and its derivatives: Pain-killers or man-killers?. Heliyon. 2024 Mar 28.
22. Choi BY, Choi NG, Marti CN, Baker SD. Benzodiazepine Adverse Reaction Cases Age 50 and Older Reported to the US Poison Centers: Healthcare Use and Major Medical Effects. Pharmacoepidemiology. 2024 Aug 31;3(3):285-96.
23. Moovendhan M. Natural pain killers from marine sources: a new frontier in neurosurgical pain management. Neurosurgical Review. 2024 Aug 28;47(1):498.
24. Tefera YG, Gray S, Nielsen S, Gelaw A, Collie A. Impact of prescription medicines on work-related outcomes in workers with musculoskeletal disorders or injuries: a systematic scoping review. Journal of Occupational Rehabilitation. 2024 Jun;34(2):398-414.
25. Laubner Sakalauskienė G, Stražnickaitė I, Miškinytė S, Zdanavičius L, Šipylaitė J, Badaras R. Impact of Prescription Opioid Detoxification on Quality of Life and Pain Levels. Clinics and Practice. 2024 Aug 8;14(4):1529-37.
26. Shah VS, Dornbos D, Hoang NA, Cua S, Rodgers B, Pezzutti D, Duenas H, Eaton R, Kreatsoulas D, Elder JB, Prevedello DM. Preoperative prescription opioid use as an independent predictor of 90-day mortality and adverse events in craniotomy and craniectomy patients. Journal of Neurosurgery. 2024 Mar 8;1(aop):1-6.
27. Wei YJ, Winterstein AG, Schmidt S, Fillingim RB, Daniels MJ, DeKosky ST, Schmidt S. Clinical and adverse outcomes associated with concomitant use of CYP2D6-metabolized opioids with antidepressants in older nursing home residents: a target trial emulation study. Annals of Internal Medicine. 2024 Aug;177(8):1058-68.
28. Plæhn G, Fuglsang T, Hindersson P, Breindahl T. Adverse effects from counterfeit and mislabeled medicine containing tapentadol and carisoprodol. Clinical Case Reports. 2024 Aug 6;12(8):e9241.
29. Al-Hamid A, Tudor C, Assi S. Exploring profile, effects and toxicity of novel synthetic opioids and classical opioids via Twitter: A qualitative study. Emerging Trends in Drugs, Addictions, and Health. 2024 Dec 1;4:100139.
30. Ifeadi CN, Agodi F. Misuse and Abuse of Prescription Drugs: An Overview. Disseminating Scholarly Research Across The Globe. 2024:27-57.